Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage?

Stefan WandererLukas AndereggenJan MrosekSepide KashefiolaslGerrit Alexander Schubert Serge MarbacherJürgen Konczalla

Published in: Journal of neurointerventional surgery (2021)

LV application after SAH seems to beneficially influence DCVS by antagonizing 5-HT- and PGF2a-triggered vasoconstriction. Considering this spasmolytic effect, LV might have a role in the treatment of SAH, additionally in selected patients suffering takotsubo cardiomyopathy.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
heart failure
traumatic brain injury
prognostic factors
patient reported outcomes
lps induced
inflammatory response
cerebral ischemia
patient reported
replacement therapy
subarachnoid hemorrhage